What Is Oramed Pharmaceuticals Inc. (ORMP) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Oramed Pharmaceuticals Inc.'s intrinsic value is estimated at a composite fair value of $5.45. Trading at $3.96, the stock is approaching fair value or slight overvaluation (implied return of +37.8%), as 6 of 10 models suggest limited further upside. The most optimistic model, RCMH-DCF, places fair value at $14.90 (+276.8%), while Bayesian DCF — the most conservative — estimates $0.39 (-90.2%). This +367.0% gap reflects genuine analytical uncertainty about Oramed Pharmaceuticals Inc.'s intrinsic worth.
What Do the Models Say About ORMP?
10 of 13 models are currently active for ORMP. Of these, 4 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates ORMP's intrinsic value at $0.39, implying -90.2% downside from the current price. See which stocks rank higher →
How Does ORMP Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, ORMP ranks #57 by Quality of Company score. CirclFi's QOC score of 7.0/10 evaluates 32 fundamental signals. A score of 7.0 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to pharmaceutical industry businesses. For Oramed Pharmaceuticals Inc., metrics like patent cliff exposure provide important context that general-purpose valuation models may underweight.
Is ORMP a Value Trap?
CirclFi's Value Trap algorithm assigns ORMP a score of 17/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Oramed Pharmaceuticals Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Oramed Pharmaceuticals Inc. scores 7.0 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +367.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ORMP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ORMP's 10 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad